Skip to content
Search

Latest Stories

Submit Guest Post

Cake Box secures £7 million funding for Ambala Foods acquisition

Cake Box, which sells fresh cream celebration cakes, placed 3.9m new shares at 180 pence each through Shore Capital Stockbrokers Ltd.

Cake Box secures £7 million funding for Ambala Foods acquisition

Cake Box, which sells fresh cream celebration cakes, placed 3.9m new shares at 180 pence each through Shore Capital Stockbrokers Ltd. (Photo: X/@eggfreecakeuk)

CAKE BOX HOLDINGS PLC has raised £7.0 million through a share offer to partially fund its acquisition of Ambala Foods Ltd, a UK-based Asian sweets manufacturer and retailer.

Cake Box, which sells fresh cream celebration cakes, placed 3.9m new shares at 180 pence each through Shore Capital Stockbrokers Ltd.


The new shares represent 8.9 per cent of the company’s total. AJ Bell reported that Cake Box shares rose 1.6 per cent to 193.00p on Wednesday morning in London.

Of the total amount raised, £210,000 came from Cake Box directors, including £100,000 from CEO Sukh Chamdal.

The company is also offering up to 111,111 new shares at 180p each to retail investors through the BookBuild platform, aiming to raise an additional £200,000.

The remaining purchase amount will be funded through a £15m term loan and existing cash.

Ambala Foods, which has been in operation since 1965, runs 22 stores in the UK and a manufacturing facility in Welwyn Garden City.

It reported a pretax profit of £1.8m on £14.0m in revenue in financial 2023.

Cake Box expects the acquisition to be earnings enhancing and has identified at least £1m in efficiency gains from integrating Ambala’s operations.

The company said it has continued to trade strongly, with Christmas and New Year’s sales exceeding £4m.

It remains confident of meeting market expectations for the financial year ending 31 March.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less